Risk of ipsilateral and contralateral cancer in BRCA mutation carriers with breast cancer

被引：3
|
作者：
Green L. [1 ]
Meric-Bernstam F. [1 ]
机构：
[1] Department of Surgical Oncology, University of Texas, M. D. Anderson Cancer Center, Houston, TX 77030
来源：
Current Breast Cancer Reports | 2011年 / 3卷 / 3期
关键词：
BRCA1; BRCA2; Contralateral breast cancer; Prophylactic mastectomy;
D O I：
10.1007/s12609-011-0047-3
中图分类号：
学科分类号：
摘要：
BRCA1 and BRCA2 mutation carriers with breast cancer have a high risk of ipsilateral breast cancer tumor recurrence (IBTR) and a high lifetime risk of contralateral breast cancer (CBC). The IBTR risk is significantly higher in women who elect breast conservation. Oophorectomy has a protective effect for both ipsilateral breast tumor recurrence and CBC. Patients with younger age of breast cancer onset have a significantly greater risk of CBC. Given the higher risk of IBTR and CBC, when indicated, patients with breast cancer should undergo genetic counseling early in their treatment course to assist them in their surgical decision-making. Knowledge of expected outcomes for BRCA1/2 mutation carriers following breast cancer treatment can help in appropriately counseling patients and personalizing cancer therapy. © 2011 Springer Science+Business Media, LLC.
引用
收藏
页码：151 / 155
页数：4
相关论文
共 50 条
  • [41] Age-specific risks of incident, contralateral and ipsilateral breast cancer among 1776 Polish BRCA1 mutation carriers
    Jan Lubinski
    Tomasz Huzarski
    Jacek Gronwald
    Cezary Cybulski
    Tadeusz Debniak
    Ping Sun
    Shana J. Kim
    Joanne Kotsopoulos
    Steven A. Narod
    Breast Cancer Research and Treatment, 2019, 174 : 769 - 774
  • [42] Age-specific risks of incident, contralateral and ipsilateral breast cancer among 1776 Polish BRCA1 mutation carriers
    Lubinski, Jan
    Huzarski, Tomasz
    Gronwald, Jacek
    Cybulski, Cezary
    Debniak, Tadeusz
    Sun, Ping
    Kim, Shana J.
    Kotsopoulos, Joanne
    Narod, Steven A.
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 174 (03) : 769 - 774
  • [43] Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer
    Kerryn W. Reding
    Jonine L. Bernstein
    Bryan M. Langholz
    Leslie Bernstein
    Robert W. Haile
    Colin B. Begg
    Charles F. Lynch
    Patrick Concannon
    Ake Borg
    Sharon N. Teraoka
    Therese Törngren
    Anh Diep
    Shanyan Xue
    Lisbeth Bertelsen
    Xiaolin Liang
    Anne S. Reiner
    Marinela Capanu
    Kathleen E. Malone
    Breast Cancer Research and Treatment, 2010, 123 : 491 - 498
  • [44] Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer
    Reding, Kerryn W.
    Bernstein, Jonine L.
    Langholz, Bryan M.
    Bernstein, Leslie
    Haile, Robert W.
    Begg, Colin B.
    Lynch, Charles F.
    Concannon, Patrick
    Borg, Ake
    Teraoka, Sharon N.
    Torngren, Therese
    Diep, Anh
    Xue, Shanyan
    Bertelsen, Lisbeth
    Liang, Xiaolin
    Reiner, Anne S.
    Capanu, Marinela
    Malone, Kathleen E.
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 123 (02) : 491 - 498
  • [45] Breast & ovarian cancer risk in BRCA mutation carriers: Implications for prevention
    Catane, R
    Halle, D
    Kaufman, B
    Eisenberg, S
    Isaacson, R
    Chemy, N
    Lahad, A
    Hornreich, G
    Beller, U
    LevyLahad, E
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 37 - 37
  • [46] Breast Cancer Following Ovarian Cancer in BRCA Mutation Carriers
    Gangi, Alexandra
    Cass, Ilana
    Paik, Daniel
    Barmparas, Galinos
    Karlan, Beth
    Dang, Catherine
    Li, Andrew
    Walsh, Christine
    Rimel, Bobbie J.
    Amersi, Farin F.
    JAMA SURGERY, 2014, 149 (12) : 1306 - 1313
  • [47] Breast cancer after ovarian cancer in BRCA mutation carriers
    Nanez, A.
    Powell, C. B.
    Garcia, C.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 256 - 256
  • [48] Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers:: a case-control study
    Narod, SA
    Brunet, JS
    Ghadirian, P
    Robson, M
    Heimdal, K
    Neuhausen, SL
    Stoppa-Lyonnet, D
    Lerman, C
    Pasini, B
    de los Rios, P
    Weber, B
    Lynch, H
    LANCET, 2000, 356 (9245): : 1876 - 1881
  • [49] Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study
    Akdeniz, Delal
    van Barele, Mark
    Heemskerk-Gerritsen, Bernadette A. M.
    Steyerberg, Ewout W.
    Hauptmann, Michael
    van de Beek, Irma
    van Engelen, Klaartje
    Wevers, Marijke R.
    Garcia, Encarnacion B. Gomez
    Ausems, Margreet G. E. M.
    Berger, Lieke P., V
    van Asperen, Christi J.
    Adank, Muriel A.
    Collee, Margriet J.
    Stommel-Jenner, Denise J.
    Jager, Agnes
    Schmidt, Marjanka K.
    Hooning, Maartje J.
    BREAST, 2022, 61 : 98 - 107
  • [50] The impact of contralateral mastectomy on mortality in BRCA1 and BRCA2 mutation carriers with breast cancer
    Narod, Steven A.
    BREAST CANCER RESEARCH AND TREATMENT, 2011, 128 (02) : 581 - 583
12345